These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 7954925)

  • 1. Synthesis of immunoadjuvant conjugates with HIV-derived peptide inducing peptide-specific antibody.
    Maruyama Y; Kurimura M; Achiwa K
    Chem Pharm Bull (Tokyo); 1994 Aug; 42(8):1709-11. PubMed ID: 7954925
    [No Abstract]   [Full Text] [Related]  

  • 2. Induction of cross-reactive cytotoxic T-lymphocyte responses specific for HIV-1 gp120 using saponin adjuvant (QS-21) supplemented subunit vaccine formulations.
    Newman MJ; Wu JY; Gardner BH; Anderson CA; Kensil CR; Recchia J; Coughlin RT; Powell MF
    Vaccine; 1997 Jun; 15(9):1001-7. PubMed ID: 9261947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design of a complete synthetic peptide-based AIDS vaccine with a built-in adjuvant.
    Nardelli B; Defoort JP; Huang W; Tam JP
    AIDS Res Hum Retroviruses; 1992 Aug; 8(8):1405-7. PubMed ID: 1466968
    [No Abstract]   [Full Text] [Related]  

  • 4. Combinatorial peptide library as an immunogen.
    Estaquier J; Ameisen JC; Auriault C; Boutillon C; Gras-Masse H; Tartar A
    Methods Mol Biol; 1998; 87():281-96. PubMed ID: 9523278
    [No Abstract]   [Full Text] [Related]  

  • 5. Increased immunogenicity of HIV envelope subunit complexed with alpha2-macroglobulin when combined with monophosphoryl lipid A and GM-CSF.
    Liao HX; Cianciolo GJ; Staats HF; Scearce RM; Lapple DM; Stauffer SH; Thomasch JR; Pizzo SV; Montefiori DC; Hagen M; Eldridge J; Haynes BF
    Vaccine; 2002 May; 20(17-18):2396-403. PubMed ID: 12009296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of a synthetic vaccine construct as antigen for the detection of HIV-induced humoral responses.
    Hewer R; Meyer D
    Vaccine; 2005 Mar; 23(17-18):2164-7. PubMed ID: 15755588
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polyvalent, recombinant HIV-1 virus-like particles: novel HIV-1 vaccine strategies.
    Wagner R; Deml L; Wolf H
    Antibiot Chemother (1971); 1994; 46():48-61. PubMed ID: 7826039
    [No Abstract]   [Full Text] [Related]  

  • 8. Immunogenicity of synthetic HIV-1 gp120 V3-loop peptide-conjugate immunogens.
    Conley AJ; Conard P; Bondy S; Dolan CA; Hannah J; Leanza WJ; Marburg S; Rivetna M; Rusiecki VK; Sugg EE
    Vaccine; 1994 Apr; 12(5):445-51. PubMed ID: 8023553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhancement of HIV type 1 vaccine immunogenicity by block copolymer adjuvants. I. Induction of high-titer, long-lasting, cross-reactive antibodies of broad isotype.
    McNicholl JM; Bond KB; Ruhadze ER; Olsen MR; Takayama K; Hunter RL
    AIDS Res Hum Retroviruses; 1998 Nov; 14(16):1457-71. PubMed ID: 9824324
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Studies on in vivo induction of HIV-1 envelope-specific cytotoxic T lymphocytes by synthetic peptides from the V3 loop region of HIV-1 IIIB gp 120.
    Nehete PN; Casement KS; Arlinghaus RB; Sastry KJ
    Cell Immunol; 1995 Feb; 160(2):217-23. PubMed ID: 7720083
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of HIV-1 by secretory IgA induced by oral immunization with a new macromolecular multicomponent peptide vaccine candidate.
    Bukawa H; Sekigawa K; Hamajima K; Fukushima J; Yamada Y; Kiyono H; Okuda K
    Nat Med; 1995 Jul; 1(7):681-5. PubMed ID: 7585151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity of synthetic HIV-1 V3 loop peptides by MPL adjuvanted pH-sensitive liposomes.
    Chang JS; Choi MJ; Kim TY; Cho SY; Cheong HS
    Vaccine; 1999 Mar; 17(11-12):1540-8. PubMed ID: 10195791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pimelautide or trimexautide as built-in adjuvants associated with an HIV-1-derived peptide: synthesis and in vivo induction of antibody and virus-specific cytotoxic T-lymphocyte-mediated response.
    Déprez B; Gras-Masse H; Martinon F; Gomard E; Lévy JP; Tartar A
    J Med Chem; 1995 Feb; 38(3):459-65. PubMed ID: 7853339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA vaccine molecular adjuvants SP-D-BAFF and SP-D-APRIL enhance anti-gp120 immune response and increase HIV-1 neutralizing antibody titers.
    Gupta S; Clark ES; Termini JM; Boucher J; Kanagavelu S; LeBranche CC; Abraham S; Montefiori DC; Khan WN; Stone GW
    J Virol; 2015 Apr; 89(8):4158-69. PubMed ID: 25631080
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of MTP-PE liposomes and interleukin-7 on induction of antibody and cell-mediated immune responses to a recombinant HIV-envelope protein.
    Bui T; Dykers T; Hu SL; Faltynek CR; Ho RJ
    J Acquir Immune Defic Syndr (1988); 1994 Aug; 7(8):799-806. PubMed ID: 8021814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of an HIV-1 peptide vaccine containing a multideterminant helper peptide linked to a V3 loop peptide 18 inducing strong neutralizing antibody responses in mice of multiple MHC haplotypes after two immunizations.
    Ahlers JD; Pendleton CD; Dunlop N; Minassian A; Nara PL; Berzofsky JA
    J Immunol; 1993 Jun; 150(12):5647-65. PubMed ID: 8515081
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaginal immunization of rats with a synthetic peptide from human immunodeficiency virus envelope glycoprotein.
    O'Hagan DT; Rafferty D; McKeating JA; Illum L
    J Gen Virol; 1992 Aug; 73 ( Pt 8)():2141-5. PubMed ID: 1645152
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of low-profile serine substitutions in the V3 loop of HIV-1 gp120 IIIB/LAI on the immunogenicity of the envelope protein.
    Peet NM; McKeating JA; de Souza JB; Roitt IM; Delves PJ; Lund T
    Virology; 1998 Nov; 251(1):59-70. PubMed ID: 9813203
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1-specific polyclonal and monoclonal antibodies raised with synthetic peptides: characterization and applications.
    Laman JD; Schellekens MM; Paddenburg D; Tersmette M; Langedijk JP; Boersma WJ; Claassen E
    Year Immunol; 1993; 7():63-8. PubMed ID: 7690509
    [No Abstract]   [Full Text] [Related]  

  • 20. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
    Kang CY; Luo L; Wainberg MA; Li Y
    Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.